Latest Period
Q1 2026
Security Snapshot
LIGAND PHARMACEUTICALS INC - Common Stock (LGND) Institutional Ownership
CUSIP: 53220K504
13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026
Institutions Reporting
355
Shares (Excl. Options)
20,792,233
Price
$199.65
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- LGND on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 20,792,233
- Total 13F value
- $4,149,134,984
- Portfolio coverage rank
- 0.01%
- Share change
- +191,309
- Value change
- +$39,257,747
- Number of holders
- 355
- Shares outstanding
- 19,948,813
- SEC-reported price per share
- $235.89
- Insider filing price
- $235.89
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LGND - LIGAND PHARMACEUTICALS INC - Common Stock is tracked under CUSIP 53220K504.
- 355 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 346 to 355 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,882,885,311 to $4,149,134,984.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 355 institutions filings for Q1 2026.
Security key
53220K504
Latest holder period
Q1 2026
13F holders
355
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
LGND full holder history
LIGAND PHARMACEUTICALS INC SEC filings
LIGAND PHARMACEUTICALS INC company facts
LIGAND PHARMACEUTICALS INC insider transactions
LIGAND PHARMACEUTICALS INC 13D/G history
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 53220K504:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
LGND
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 14% | -6.9% | $502,945,206 | -$18,898,723 | 2,839,251 | -3.6% | BlackRock, Inc. | 30 Sep 2025 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.6% | $236,737,830 | 1,109,154 | Vanguard Portfolio Management | 31 Mar 2026 | |||
| JANUS HENDERSON GROUP PLC | 5.3% | -3.3% | $184,646,839 | -$3,251,582 | 1,042,378 | -1.7% | JANUS HENDERSON GROUP PLC | 30 Sep 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5% | $212,935,641 | 997,637 | Vanguard Capital Management | 31 Mar 2026 |
As of 31 Mar 2026, 355 institutional investors reported holding 20,792,233 shares of LIGAND PHARMACEUTICALS INC - Common Stock (LGND). This represents 104% of the company’s total 19,948,813 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
75%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 15% | 2,961,923 | +0.74% | 0.01% | $591,347,927 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 5.5% | 1,100,267 | 0% | 0.01% | $219,668,307 |
| JANUS HENDERSON GROUP PLC | 5.1% | 1,009,891 | +1.5% | 0.1% | $201,622,937 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.3% | 848,089 | 0% | 0% | $169,320,969 |
| Invesco Ltd. | 4.1% | 823,604 | +59% | 0.03% | $164,432,539 |
| STATE STREET CORP | 3.9% | 778,856 | +3.7% | 0.01% | $155,498,600 |
| FMR LLC | 3% | 596,127 | +2.9% | 0.01% | $119,016,815 |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 2.9% | 573,312 | -11% | 0.2% | $114,462,000 |
| FRANKLIN RESOURCES INC | 2.9% | 573,177 | +16% | 0.03% | $114,434,772 |
| Chicago Capital, LLC | 2.8% | 561,675 | +0.04% | 3% | $112,138,378 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8% | 558,934 | +13% | 0.01% | $111,608,727 |
| CONGRESS ASSET MANAGEMENT CO | 2.5% | 504,637 | +5.1% | 0.72% | $100,750,777 |
| Stephens Investment Management Group LLC | 2.5% | 494,670 | -1.3% | 1.4% | $98,760,866 |
| DIMENSIONAL FUND ADVISORS LP | 2.1% | 425,230 | -1.8% | 0.02% | $84,887,195 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 2.1% | 411,543 | -19% | 0.03% | $82,164,560 |
| GOLDMAN SACHS GROUP INC | 1.9% | 381,111 | -11% | 0.01% | $76,088,811 |
| LOOMIS SAYLES & CO L P | 1.8% | 353,209 | -7.7% | 0.1% | $70,518,177 |
| DEUTSCHE BANK AG\ | 1.5% | 306,111 | -0.57% | 0.02% | $61,115,061 |
| VICTORY CAPITAL MANAGEMENT INC | 1.5% | 303,224 | +18% | 0.04% | $60,538,672 |
| RICE HALL JAMES & ASSOCIATES, LLC | 1.4% | 283,567 | +1.4% | 3.2% | $56,614,152 |
| Ranger Investment Management, L.P. | 1.3% | 267,943 | -0.76% | 3.9% | $53,494,820 |
| NORTHERN TRUST CORP | 1.3% | 254,158 | +1.4% | 0.01% | $50,742,645 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 1.1% | 212,888 | -41% | 0.01% | $42,503,090 |
| ASHFORD CAPITAL MANAGEMENT INC | 1% | 207,565 | -2.9% | 5.1% | $41,440,352 |
| Private Capital Management, LLC | 1% | 201,381 | -3.6% | 4.1% | $40,205,717 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
49
Latest
Q1 2026
Rows shown
1-25 of 49
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 20,792,233 | $4,149,134,984 | +$39,257,747 | $199.65 | 355 |
| 2025 Q4 | 20,533,086 | $3,882,885,311 | -$110,777,533 | $189.07 | 346 |
| 2025 Q3 | 20,501,821 | $3,631,336,857 | +$254,065,498 | $177.14 | 310 |
| 2025 Q2 | 19,192,378 | $2,181,883,515 | +$57,084,248 | $113.68 | 268 |
| 2025 Q1 | 18,695,299 | $1,968,273,762 | +$46,599,577 | $105.14 | 258 |
| 2024 Q4 | 18,236,878 | $1,954,099,547 | +$14,647,324 | $107.15 | 255 |
| 2024 Q3 | 18,111,561 | $1,812,508,826 | +$78,053,426 | $100.09 | 239 |
| 2024 Q2 | 17,257,543 | $1,454,006,662 | +$80,527,643 | $84.26 | 231 |
| 2024 Q1 | 16,498,593 | $1,205,830,157 | +$33,853,892 | $73.10 | 220 |
| 2023 Q4 | 16,143,355 | $1,152,971,286 | +$28,617,779 | $71.42 | 207 |
| 2023 Q3 | 15,788,358 | $946,166,941 | +$7,782,713 | $59.92 | 194 |
| 2023 Q2 | 15,574,833 | $1,123,051,822 | +$43,367,440 | $72.10 | 202 |
| 2023 Q1 | 14,933,765 | $1,098,173,916 | +$24,759,078 | $73.56 | 208 |
| 2022 Q4 | 14,719,986 | $983,617,158 | -$15,487,378 | $66.80 | 194 |
| 2022 Q3 | 14,858,763 | $1,279,578,932 | -$9,219,791 | $86.11 | 196 |
| 2022 Q2 | 14,931,494 | $1,332,246,388 | -$60,732,119 | $89.22 | 183 |
| 2022 Q1 | 15,633,927 | $1,758,540,556 | -$96,543,968 | $112.49 | 191 |
| 2021 Q4 | 16,269,930 | $2,512,534,392 | -$20,671,000 | $154.46 | 213 |
| 2021 Q3 | 16,404,211 | $2,285,781,890 | +$72,094,291 | $139.32 | 203 |
| 2021 Q2 | 15,890,032 | $2,084,646,847 | +$57,293,258 | $131.19 | 208 |
| 2021 Q1 | 15,419,613 | $2,350,478,943 | -$1,007,217,320 | $152.45 | 220 |
| 2020 Q4 | 22,774,344 | $2,264,990,431 | -$7,636,839 | $99.45 | 232 |
| 2020 Q3 | 22,870,335 | $2,179,670,768 | +$68,808,132 | $95.32 | 248 |
| 2020 Q2 | 22,068,878 | $2,469,185,512 | -$52,085,687 | $111.85 | 253 |
| 2020 Q1 | 22,949,296 | $1,668,870,325 | -$13,474,819 | $72.72 | 250 |